GlycoMimetics, Inc. Reports First Quarter 2015 Results
AITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2015.
“GlycoMimetics used the first quarter to focus on development activities, primarily preparing to initiate enrollment in the GMI-1271 clinical trial in acute myeloid leukemia (AML), which is planned to begin in the second quarter. In addition, our partner Pfizer continues to prepare for initiation of a Phase 3 study of rivipansel in sickle cell disease. With the recent update from Pfizer, we look forward to the initiation of that study now planned for mid-2015,” said Rachel King, CEO of GlycoMimetics.
Help employers find you! Check out all the jobs and post your resume.
“GlycoMimetics used the first quarter to focus on development activities, primarily preparing to initiate enrollment in the GMI-1271 clinical trial in acute myeloid leukemia (AML), which is planned to begin in the second quarter. In addition, our partner Pfizer continues to prepare for initiation of a Phase 3 study of rivipansel in sickle cell disease. With the recent update from Pfizer, we look forward to the initiation of that study now planned for mid-2015,” said Rachel King, CEO of GlycoMimetics.
Help employers find you! Check out all the jobs and post your resume.